Cadrenal Therapeutics, Inc.
New Form D on file · 2026-07-15 · the record
What the record says
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $8.84M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Use of proceeds, as written on the filing
While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.
Checked away from the filing. What is below does not come from the record on sec.gov.
Cadrenal Therapeutics is developing novel and differentiated biopharmaceutical products that bridge critical gaps in current acute and chronic anticoagulant therapy.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Company officers on record
On the filing as: Executive Officer, Director.
Quang Pham is named as Chairman of the Board and Chief Executive Officer on the Form D that Cadrenal Therapeutics, Inc. filed with the SEC on 15 July 2026, one of 7 people that filing names.
On the filing as: Executive Officer.
John Sharp is named as Interim Chief Financial Officer on the Form D that Cadrenal Therapeutics, Inc. filed with the SEC on 15 July 2026, one of 7 people that filing names.
On the filing as: Executive Officer.
James Ferguson is named as Chief Medical Officer on the Form D that Cadrenal Therapeutics, Inc. filed with the SEC on 15 July 2026, one of 7 people that filing names.
On the filing as: Executive Officer.
Jeffrey Cole is named as Chief Operating Officer on the Form D that Cadrenal Therapeutics, Inc. filed with the SEC on 15 July 2026, one of 7 people that filing names.
Lee Golden is named as Director on the Form D that Cadrenal Therapeutics, Inc. filed with the SEC on 15 July 2026, one of 7 people that filing names.
John Murphy is named as Director on the Form D that Cadrenal Therapeutics, Inc. filed with the SEC on 15 July 2026, one of 7 people that filing names.
Glynn Wilson is named as Director on the Form D that Cadrenal Therapeutics, Inc. filed with the SEC on 15 July 2026, one of 7 people that filing names.
7 people named on the filing — 4 holding an executive role and 3 as directors only.
Named as of the 2026-07-15 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
- 7 people named on the filing — 4 holding an executive role and 3 as directors only.
No investor is drawn from a Form D — the form states how many invested and never who.
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Cadrenal Therapeutics, Inc.
- Source Check — verify Quang X. Pham's other claims against the registers that hold them.
- INVEST — size up this raise on the figures the filing states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Quang X. Pham for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Cadrenal Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Cadrenal Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. FoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-26 (cadrenal.com).